InSphero, a Schlieren, Switzerland-based 3D cell culture company, raised CHF 20m in Series C financing.
The family investment office of a globally active entrepreneur represented through Zug, Switzerland-based HP Wild Holding AG made the investment.
The company intends to use the funds to expand global operations (into North American scientific staff and operations) and product portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing, and develop new products and applications based on its technology.
Launched in 2010 by Dr. Jan Lichtenberg, CEO, InSphero provides pharmaceutical, chemical and cosmetics companies with solutions for organotypic 3D cell culture models and body-on-a-chip systems. Its pipeline includes 3D liver, skin, heart, brain and tumor models developed for toxicity testing and disease modeling, as well as next-generation 3D cell culture platforms.